[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345642-105":59,"doc-detail-345642-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","erbb2her2-landscape-and-prognostic-impact-large-scale-real-world-analysis-across-solid-cancers","ERBB2/HER2 landscape and prognostic impact - large-scale, real-world analysis across solid cancers","","Evaluates HER2 protein expression by immunohistochemistry (IHC) and its prognostic impact alongside ERBB2 genomic alterations in a large real-world molecularly profiled dataset. Analyzes 206,750 tumors for ERBB2 copy number alterations and pathogenic mutations using next-generation sequencing, and 88,530 samples for HER2 IHC (0, 1+, 2+, 3+), with whole-transcriptome RNA assessment. Overall survival is derived from real-world insurance claims, and results link ERBB2 alteration patterns and HER2 IHC categories to survival outcomes across cancers.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/erbb2her2-landscape-and-prognostic-impact-large-scale-real-world-analysis-across-solid-cancers/345642/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/erbb2her2-landscape-and-prognostic-impact-large-scale-real-world-analysis-across-solid-cancers/345642.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What data sources were used to assess ERBB2 and HER2 in real-world patients?","Question",{"text":113,"@type":114},"The study used molecularly profiled real-world patients from Caris Life Sciences and combined next-generation sequencing data for ERBB2 alterations with HER2 IHC results and whole-transcriptome RNA evaluation, while overall survival was based on real-world insurance claims.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were HER2 protein expression levels categorized in the study?",{"text":118,"@type":114},"HER2 IHC data were stratified into four groups: 0, 1+, 2+, and 3+.",{"name":120,"@type":111,"acceptedAnswer":121},"What key relationship did the study find between ERBB2 alterations and survival?",{"text":122,"@type":114},"The study reported statistically significant associations linking HER2 IHC positivity with ERBB2 pathogenic mutations and/or amplifications in subsets of tumors, and it observed survival advantages across HER2 IHC categories, with HRs reported relative to the baseline group.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},345642,1790212093,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","ORIGINAL ARTICLE  \nERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers  \nA. Shreenivas1 , 2 ∗, A. Elliott3, T. Corbiere4, H.-Z. Chen1, B. George1, M. Kamgar1, S. Chakrabarti5, A. Desai6,  \nD. Bracken-Clarke7, E. Xue7, C. S. Floudas7, J. Thomas8, J. Xiu9, G. Sledge9, E. S. Antonarakis10, Y. Boumber6 &  \nR. Kurzrock1 , 11, 12 ∗  \n1Department Oncology, Froedtert Hospital & Medical College of Wisconsin, Milwaukee; 2City of Hope National Medical Center, Duarte; 3Clinical and Translational Research, Caris Life Sciences - Headquarters, Irving; 4Medical Affairs Department, Caris Life Sciences -Arizona Office, Phoenix; 5Medical Oncology Department, University Hospitals Seidman Cancer Center, Cleveland; 6Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham; 7Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda; 8Department of Oncology, USC-University of Southern California-Norris Comprehensive Cancer Center, Los Angeles; 9Clinical and Translational Research, Caris Life Sciences-Lab & Specimen Receiving, Phoenix; 10Division of Hematology, Oncology and Transplantation, Department of Medicine, Masonic Cancer Center-University of Minnesota, Minneapolis, USA; 11WIN Consortium, Chevilly-Larue, France; 12Department of Oncology, University of Nebraska, Omaha, USA  \nAvailable online xxx  \nBackground: We evaluated the frequency and prognostic impact of human epidermal growth factor receptor 2 (HER2) protein expression [immunohistochemistry (IHC)] and correlations with ERBB2 genomic alterations in a large database of molecularly profiled real-world patients (Caris Life Sciences, Phoenix, AZ) .  \nMaterials and methods: We analyzed 206 750 tumors for ERBB2 copy number alterations and pathogenic mutations (using next-generation sequencing) and 88 530 samples for HER2 IHC data (stratified as 0, 1+, 2+, or 3+) . RNA (whole transcriptome) was also evaluated. Overall survival (OS) was based on real-world insurance claims.  \nResults: ERBB2 amplifications and/or mutations were found in a subset of multiple cancer types. ERBB2 amplifications were often but not always associated with higher HER2 IHC expression. ERBB2 pathogenic mutations and ERBB2 amplifications correlated significantly across cancers and in some cancer subtypes. Statistically significant associations with HER2 IHC positivity were also identified in a subgroup of tumors exhibiting mutations, even without amplifications. ERBB2 transcripts were markedly increased among HER2 IHC 3+ tumors. Median OS for HER2 (3+, 2+, 1+, and 0+) tumors were 30.6, 26.9, 26.5, and 23 months, respectively [hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.77-0.83; HR 0.89, 95% CI 0.87-0.91; and HR 0.90, 95% CI 0.88-0.92, respectively (P \u003C 0.001)] . However, survival advantages observed in the overall cohort appeared largely driven by breast and gastric cancers for which HER2-targeted therapies are available.  \nConclusion: Complex relationships between ERBB2 alterations and HER2 IHC expression exist, including increased expression in non—ERBB2-amplified tumors with pathogenic mutations. Importantly, ERBB2/HER2 amplification and/or mutation rates as well as transcript and protein expression varied between cancers and within cancer types, emphasizing the need for individual assessment.  \nKey words: cancer, ERBB2, genomics, HER2, immunohistochemistry, RNA  \nINTRODUCTION  \nHuman epidermal growth factor receptor 2 (HER2) is a tyrosine kinase receptor encoded by the ERBB2 gene. HER2 expression is observed across diverse types of tumors. In an  \n*Correspondence to: Dr Aditya Shreenivas, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA 91010, USA. Tel: +1-626-746-5288  \nE-mail: [ashreenivas@coh.org](ashreenivas@coh.org) (A. Shreenivas).  \nDr Razelle Kurzrock, Froedtert & The Medical College of Wisconsin, 9200 W. Wisconsin Ave, Milwaukee, WI 53226, USA. Tel: +1","cbCair7PgEUA1BNK","https://ap.wps.com/l/cbCair7PgEUA1BNK","pdf",1777443,"English","# Background\n# Materials and methods\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"What data sources were used to assess ERBB2 and HER2 in real-world patients?\",\"answer\":\"The study used molecularly profiled real-world patients from Caris Life Sciences and combined next-generation sequencing data for ERBB2 alterations with HER2 IHC results and whole-transcriptome RNA evaluation, while overall survival was based on real-world insurance claims.\"},{\"question\":\"How were HER2 protein expression levels categorized in the study?\",\"answer\":\"HER2 IHC data were stratified into four groups: 0, 1+, 2+, and 3+.\"},{\"question\":\"What key relationship did the study find between ERBB2 alterations and survival?\",\"answer\":\"The study reported statistically significant associations linking HER2 IHC positivity with ERBB2 pathogenic mutations and/or amplifications in subsets of tumors, and it observed survival advantages across HER2 IHC categories, with HRs reported relative to the baseline group.\"}]","ERBB2/HER2 landscape and prognostic impact - large-scale, real-world analysis across solid cancers | PDF",1790058425,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/757c2b225b8db87a7b34c1bd22f76f9f.webp",983,1269,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d7734efebcfc4419774afa1eec110eda.webp",982,1268,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bdb8ac5ad6de8925712f3dbe6462fb48.webp",981,1266,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ef1e20be995e64da04b8fb28865b20be.webp",980,1265]